Central Institute for Experimental Animals

Japan Science and Technology Agency

Keio University

University of Yamanashi

Tokai University Educational System

Renascience Co., Ltd.

Cmic Co., Ltd.

Kiyoshi Ando

Tatsuji Nomura

Naoki Yamamoto

Tatsutoshi Nakahata

Koichiro Tsuji

Kazuo Sugamura

Mamoru Ito

Kimio Kobayashi

Sonoko Habu

Yoshio Koyanagi

Yasuhiko Tabata

Hideyuki Okano

Toshio Miyata

Yoshiaki Toyama

Masaya Nakamura

Yonehiro Kanemura

Hiromi Sakamoto

Takashi Yahata

Kanji Sugita

Yoshikuni Tanioka

Hidezo Mori

Etsuro Tanaka

Harukazu Iseki

Naoto Fukuyama

Hirofumi Kasahara

According to the present invention, there is provided a pharmaceutical composition for treating Philadelphia chromosome positive lymphocytic leukemia, including a thalidomide derivative and BCR-ABL tyrosine kinase inhibitor. According to the present invention there is also provided a method of treating Philadelphia chromosome positive lymphocytic leukemia, including administering a thalidomide derivative and a BCR-ABL tyrosine kinase inhibitor to a patient suffering from Philadelphia chromosome positive lymphocytic leukemia.

Therapeutic agent or treatment method for Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL) having IKZF1 mutation

Provided is a novel use of a plasminogen activator inhibitor-1 inhibitor (PAI-1 inhibitor) that is used as an active ingredient of an agent for controlling a tumor stem cell, an agent for enhancing the antitumor effect of an antitumor agent, an agent for tumor chemotherapy, a stem-cell protecting drug, or a hematopoietic disorder improving agent.

Use for PAI-1 inhibitor

The present invention provides an immunodeficient mouse (NOG mouse) suitable for engraftment, differentiation and proliferation of heterologous cells, and a method of producing such a mouse. This mouse is obtained by backcrossing a C.B-17-scid mouse with an NOD/Shi mouse, and further backcrossing an interleukin 2-receptor &#x3b3;-chain gene-knockout mouse with the thus backcrossed mouse. It is usable for producing a human antibody and establishing a stem cell assay system, a tumor model and a virus-infection model.

[object Object]

A method for creating a monkey model of spinal cord injury, which includes exposing the dura mater of the cervical cord of a monkey and applying a load on the dura mater; the thus-created monkey model of spinal cord injury; and a method for evaluating a therapeutic drug for spinal cord injury by use of this model. According to the present invention, it is possible to create a monkey which is close to the human and thus useful as a model of human spinal cord injury. This model enables proper evaluation of therapeutic effects of various drugs on spinal cord injury. Through use of this model, it has been confirmed for the first time that transplantation therapy of human neural stem cells is efficacious against spinal cord injury.

Method of constructing spinal injury model monkey and utilization thereof

A nucleic acid-complex, containing a nucleic acid and a positively charged, water-insoluble biodegradable polymer, is disclosed. The complex has properties of sustainedly releasing a desired nucleic acid, especially DNA, to a site. The complex can be taken up by phagocytes such as macrophages and delivered to a target site, allowing the function of the nucleic acid to be exhibited in a target specific manner.

Nucleic acid-containing complex

Method of producing a mouse suitable for the engraftment, differentiation and proliferation of heterologous cells, mouse produced by this method and use of the mouse

Growing community of inventors

Kanagawa, Japan

Kiyoshi Ando